ANZICS CTG Endorsed Study

ICU-ROX

A phase 2b, multi-centre, randomised, single blinded clinical trial parallel groups comparing liberal vs. conservative oxygen therapy in mechanically ventilated adults in the Intensive Care Unit (ICU).

Study Description

ICU-ROX is a phase 2b, multi-centre, randomised, single blinded clinical trial parallel groups comparing liberal vs. conservative oxygen therapy in mechanically ventilated adults in the Intensive Care Unit (ICU).

Our study hypothesis is that a conservative approach to oxygen therapy, which minimises unnecessary exposure to hyperoxaemia, will increase ventilator-free days compared to a more liberal approach to oxygen therapy which does not specifically aim to avoid exposure to hyperoxaemia.

Management Committee

Paul Young (Chair), Richard Beasley, Rinaldo Bellomo, Victoria Bennett, Adam Deane, Glenn Eastwood, Simon Finfer, Ross Freebairn, Natalie Linke (Project Manager) Ed Litton, Colin McArthur, Shay McGuinness, Diane Mackle (Project Manager) and Rakshit Panwar.

Administering Institution

Medical Research Institute of New Zealand

Collaborators

ANZIC Research Centre, Monash University

Sample Size

1000 patients

Funding

Health Research Council of New Zealand Project Grant NZ$1,404, 525

Project Status as of June 2018

ICU-ROX completed recruitment on 29 May 2018, and the final Day 180 follow-up is due on 25 November 2018. The protocol summary and analysis plan has been published. Plans for presentation and publication are yet to be finalised.

Reference

CTG1415-04
ACTRN12615000957594

Contact

Paul Young (email)